This clinical trial is focused on studying a condition known as Relapsing-Remitting Multiple Sclerosis, which is a type of multiple sclerosis characterized by periods of new or increasing symptoms followed by periods of partial or complete recovery. The study is comparing two treatments: Ocrelizumab and Fingolimod. Ocrelizumab is given as a solution for infusion, which means it is administered directly into the bloodstream through a vein, while Fingolimod is taken orally in the form of hard capsules. The trial also includes a placebo, which is a substance with no active medication, to help understand the effects of the treatments better.

The purpose of the study is to evaluate the safety and effectiveness of Ocrelizumab compared to Fingolimod in children and adolescents with Relapsing-Remitting Multiple Sclerosis. Participants in the study will receive either Ocrelizumab or Fingolimod, and their health will be monitored over a period of time to observe any changes in their condition. The study aims to determine if Ocrelizumab is not inferior to Fingolimod in terms of reducing the annualized relapse rate, which is a measure of how often relapses occur over a year.

Throughout the study, participants will undergo various assessments, including MRI scans, to check for changes in the brain and to monitor the number of new or enlarging lesions. The study will also track any side effects or adverse events that may occur. This research is important for understanding how these treatments can help manage Relapsing-Remitting Multiple Sclerosis in younger patients and to ensure their safety and effectiveness.